LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade

Oncogene

Volumn 34, Issue 1, 2013, Pages 73-83

  Tanaka, I ^a,b   Osada, H ^a,b   Fujii, M ^a   Fukatsu, A ^a,b   Hida, T ^a   Horio, Y ^a   Kondo, Y ^a   Sato, A ^c   Hasegawa, Y ^b   Tsujimura, T ^c   Sekido, Y ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

AJUBA; Hippo pathway; LATS2; Malignant mesothelioma; YAP

Indexed keywords

AJUBA PROTEIN, HUMAN; HIPPO PROTEIN, HUMAN; LIM PROTEIN; MERLIN; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

CELL ADHESION; CELL PROLIFERATION; CYTOPLASM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; LUNG TUMOR; MESOTHELIOMA; METABOLISM; PHENOTYPE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LENTIVIRUS; LIM DOMAIN PROTEINS; LUNG NEOPLASMS; MESOTHELIOMA; NEUROFIBROMIN 2; PHENOTYPE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84925284726     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.528     Document Type: Article

References (48)

1. Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer 2004; 28: 93-174.
2. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 2008; 9: 147-157.
3. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011; 89: 716-724.
4. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012; 227: 44-58.
5. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-1603.
6. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408.
7. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
8. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002; 29: 2-17.
9. Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 2010; 101: 1-6.
10. Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995; 92: 10854-10858.
11. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995; 55: 1227-1231.
12. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120-1133.
13. Saucedo LJ, Edgar BA. Filling out the Hippo pathway. Nat Rev Mol Cell Biol 2007; 8: 613-621.
14. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005; 122: 421-434.
15. Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D et al. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002; 110: 467-478.
16. Badouel C, Garg A, McNeill H. Herding Hippos: regulating growth in flies and man. Curr Opin Cell Biol 2009; 21: 837-843.
17. Zhao B, Ye X, Yu J, Li L, Li W, Li S et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22: 1962-1971.
18. Mizuno T, Murakami H, Fujii M, Ishiguro F, Tanaka I, Kondo Y et al. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene 2012; 31: 5117-5122.
19. Yokoyama T, Osada H, Murakami H, Tatematsu Y, Taniguchi T, Kondo Y et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 2008; 29: 2139-2146.
20. Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 2011; 71: 873-883.
21. Feng Y, Longmore GD. The LIM protein Ajuba influences interleukin-1-induced NF-kappaB activation by affecting the assembly and activity of the protein kinase Czeta/p62/TRAF6 signaling complex. Mol Cell Biol 2005; 25: 4010-4022.
22. Locasale JW, Shaw AS, Chakraborty AK. Scaffold proteins confer diverse regulatory properties to protein kinase cascades. Proc Natl Acad Sci USA 2007; 104: 13307-13312.
23. Shaw AS, Filbert EL. Scaffold proteins and immune-cell signalling. Nat Rev Immunol 2009; 9: 47-56.
24. Levchenko A, Bruck J, Sternberg PW. Scaffold proteins may biphasically affect the levels of mitogen-activated protein kinase signaling and reduce its threshold properties. Proc Natl Acad Sci USA 2000; 97: 5818-5823.
25. Burack WR, Shaw AS. Signal transduction: hanging on a scaffold. Curr Opin Cell Biol 2000; 12: 211-216.
26. Abe Y, Ohsugi M, Haraguchi K, Fujimoto J, Yamamoto T. LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and spindle organization during mitosis. FEBS Lett 2006; 580: 782-788.
27. Das Thakur M, Feng Y, Jagannathan R, Seppa MJ, Skeath JB, Longmore GD et al. Ajuba LIM proteins are negative regulators of the Hippo signaling pathway. Curr Biol 2010; 20: 657-662.
28. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-2761.
29. Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 2006; 66: 2562-2569.
30. Polesello C, Huelsmann S, Brown NH, Tapon N. The Drosophila RASSF homolog antagonizes the hippo pathway. Curr Biol 2006; 16: 2459-2465.
31. Sasaki H. Mechanisms of trophectoderm fate specification in preimplantation mouse development. Dev Growth Differ 2010; 52: 263-273.
32. Alvarez-Fernandez M, Halim VA, Krenning L, Aprelia M, Mohammed S, Heck AJ et al. Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1. EMBO Rep 2010; 11: 452-458.
33. Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 2007; 1775: 92-102.
34. Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 2005; 25: 10875-10894.
35. Fu Z, Malureanu L, Huang J, Wang W, Li H, van Deursen JM et al. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol 2008; 10: 1076-1082.
36. Wang IC, Chen YJ, Hughes DE, Ackerson T, Major ML, Kalinichenko VV et al. FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J Biol Chem 2008; 283: 20770-20778.
37. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 2007; 67: 8293-8300.
38. Hirota T, Kunitoku N, Sasayama T, Marumoto T, Zhang D, Nitta M et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003; 114: 585-598.
39. Ferrand A, Chevrier V, Chauvin JP, Birnbaum D. Ajuba: a new microtubule-associated protein that interacts with BUBR1 and Aurora B at kinetochores in metaphase. Biol Cell 2009; 101: 221-235.
40. Benzinger A, Muster N, Koch HB, Yates 3rd JR, Hermeking H. Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Mol Cell Proteomics 2005; 4: 785-795.
41. Mo JS, Yu FX, Gong R, Brown JH, Guan KL. Regulation of the Hippo-YAP pathway by protease-activated receptors (PARs). Genes Dev 2012; 26: 2138-2143.
42. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012; 150: 780-791.
43. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 2012; 26: 54-68.
44. Boggiano JC, Fehon RG. Growth control by committee: intercellular junctions, cell polarity, and the cytoskeleton regulate Hippo signaling. Dev Cell 2012; 22: 695-702.
45. Wada K, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development 2011; 138: 3907-3914.
46. Sansores-Garcia L, Bossuyt W, Wada K, Yonemura S, Tao C, Sasaki H et al. Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J 2011; 30: 2325-2335.
47. Marie H, Pratt SJ, Betson M, Epple H, Kittler JT, Meek L et al. The LIM protein Ajuba is recruited to cadherin-dependent cell junctions through an association with alpha-catenin. J Biol Chem 2003; 278: 1220-1228.
48. Fujii M, Toyoda T, Nakanishi H, Yatabe Y, Sato A, Matsudaira Y et al. TGF-beta synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med 2012; 209: 479-494.